Biosimilar approvals, pricing and market entry
Biosimilar approvals, pricing and market entry
Chile’s former top drug regulator says faster approvals mean little if coverage stalls, and wants the medicines agency separated administratively from the Institute of Public Health.
mAbxience and Sandoz have signed a global collaboration agreement to develop and commercialize a biosimilar candidate of emicizumab, targeting the haemophilia A market valued at $5.7 billion.
Argentina’s Grupo Insud is building a biologics platform: mAbxience exports biosimilars across three continents while Sinergium anchors Latin America’s mRNA vaccine sovereignty.
ANVISA’s approval of the 8th edition of Farmacopeia Brasileira updates national quality standards for medicines and active pharmaceutical ingredients, reshaping registration requirements across Brazil’s pharmaceutical market.
You must be logged in to post a comment.